Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients With Solid Tumors - a Phase 0, Open Label, PET/CT Molecular Imaging Basket Trial

NCT06645808 is registered in ClinicalTrials.gov with Var2 Pharmaceuticals as lead sponsor.

NCT NCT06645808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06645808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients With Solid Tumors - a Phase 0, Open Label, PET/CT Molecular Imaging Basket Trial
Lead sponsor
Var2 Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
December 10, 2024
Completion date
September 30, 2026
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma, breast cancer, chondrosarcoma, colon carcinoma, esophageal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, lung carcinoma, osteosarcoma, pancreas carcinoma, rectal carcinoma, soft tissue sarcoma (sts), solid tumor